Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 65

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 65
---
, or ultimately be unable to complete, the development and commercialization of our Product Candidates. |

| • |     | We depend on enrollment of patients in our clinical trials for our Product Candidates. If we experience delays                                                                                       
 or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected. |

| • |     | Our Product Candidates may be associated with serious adverse events or undesirable side effects or have other                                                                               
 properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. |

| • |     | We have conducted and may continue to conduct clinical trials for our Product Candidates in international      
 sites, and the applicable regulatory authority may not accept data from trials conducted in foreign locations. |

| • |     | Interim, “top-line” or preliminary data from our clinical                                                                                                                                                           
 trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. |

| • |     | We may attempt to secure approval from the U.S. Food and Drug Administration (the “FDA”), the                                                                                                                                                       
 National Medical Products Administration (“NMPA”) or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical        
 trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, the NMPA or comparable foreign regulatory    
 authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, the NMPA or comparable foreign regulatory authorities may seek to withdraw accelerated approval. |

| • |     | We have only one Product Candidate, rademikibart, currently in clinical development. If we are unable to                          
 successfully develop our Product Candidates or experience significant delays in doing so, our business will be materially harmed. |

| • |     | Our approach to the discovery and development of Product Candidates based on potent T cell modulation activity                                                                                                                           
 is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our Product Candidates or render our approach obsolete. |

| • |     | We